Sun Pharma update on USFDA inspection of its Dadra facility
Receives copy of EIR from USFDA
Sun Pharmaceuticals Industries has received a communication from the US FDA releasing a copy of the Establishment Inspection Report (EIR) in respect of the inspection of Company's Dadra facility. Earlier, the USFDA had issued Form- 483 observation letter post inspection completed on 13 April 2017.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content